A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Lees, A J
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. [electronic resource] - European neurology 1987 - 126-34 p. digital
Publication Type: Journal Article
0014-3022
10.1159/000116207 doi
Benserazide--pharmacokinetics
Circadian Rhythm
Delayed-Action Preparations
Drug Combinations--pharmacokinetics
Female
Humans
Hydrazines--therapeutic use
Levodopa--blood
Male
Middle Aged
Movement Disorders--drug therapy
Parkinson Disease--complications
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. [electronic resource] - European neurology 1987 - 126-34 p. digital
Publication Type: Journal Article
0014-3022
10.1159/000116207 doi
Benserazide--pharmacokinetics
Circadian Rhythm
Delayed-Action Preparations
Drug Combinations--pharmacokinetics
Female
Humans
Hydrazines--therapeutic use
Levodopa--blood
Male
Middle Aged
Movement Disorders--drug therapy
Parkinson Disease--complications